Use of a compound (I) interacting with brain-derived nerve growth factor (BDNF)-signal transduction cascade for the production of a medicament to treat phantom phenomena of acute tinnitus and/or phantom pain in human or animal. Independent claims are also included for: (1) diagnosing phantom phenomena of the acute tinnitus and/or phantom pain in human or animal, comprising supplying a biological sample, determining the level of the expression of BDNF in the biological sample, comparing the level with a reference value from a healthy organism, and correlating a level lying over the healthy organism with a positive diagnosis and (2) treating phantom phenomena of the acute tinnitus and/or phantom pain in human or animal, comprising supplying a medicament that exhibits a substance interacting with BDNF signal transduction cascade, and applying the medicament locally to the organism, and optionally repeating the method. ACTIVITY : Auditory Analgesic. MECHANISM OF ACTION : Brain-derived nerve growth factor (BDNF)-signal transduction cascade blocker BDNF-signal transduction cascade inhibitor Gamma aminobutyric acid receptor agonist L-type-Ca ++>-channel antagonist Cyclic adenosine monophosphate response element binding protein (CREP) antagonist Glutamate antagonist Mitogen activated protein-kinase-inhibitor Calmodulin-dependent kinase-inhibitor Tyrosine kinase linked receptor (trkB) antagonist. The ability of (I) to inhibit BDNF-signal transduction cascade was tested in cochlea. (I) Significantly removed the expressions of BNDF Exon-IV.
